Woodline Partners LP Prometheus Biosciences, Inc. Transaction History

Woodline Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $534,784 - $652,793	5,169 Added 1.66%	317,113 $34 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $1.23 Million - $4.01 Million	34,207 Added 12.32%	311,944 $34.3 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $25.7 Million - $53.9 Million	-913,924 Reduced 76.69%	277,737 $16.4 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $16.6 Million - $28.9 Million	741,403 Added 164.66%	1,191,661 $33.6 Million
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $6.02 Million - $10 Million	199,932 Added 79.87%	450,258 $17 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $953,338 - $1.69 Million	42,789 Added 20.62%	250,326 $9.9 Million
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $101,420 - $130,890	4,855 Added 2.4%	207,537 $4.92 Million
Q2 2021 Aug 16, 2021	SELL	$16.8 - $29.65 $128,385 - $226,585	-7,642 Reduced 3.63%	202,682 $4.98 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $3.47 Million - $5.32 Million	210,324 New	210,324 $3.84 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.